Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07157254 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

Study acronym: Aurora
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised at 21 of 21 sitesv19 Show 1 more changeShow less
    • Site details revised at 21 of 21 sites
  2. Study sites revised (21)v18 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (21)v17 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (21)v16 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (21)v15 See this version in full on ClinicalTrials.gov ↗
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites revised (21)v14 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 22 to 21v13
  3. Study sites revised (22)v12 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (22)v11 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (22)v10 See this version in full on ClinicalTrials.gov ↗
  6. 2 versions Re-verified since Jan 16, 2026, no change to tracked fieldsv8-v9
  7. Study sites revised (22)v7 See this version in full on ClinicalTrials.gov ↗
  8. Re-verified, no change to tracked fieldsv6
  9. Study sites revised (22)v5 See this version in full on ClinicalTrials.gov ↗
  10. Study sites revised (22)v4 See this version in full on ClinicalTrials.gov ↗
  11. Study sites: 1 to 22 Start date changed from estimate of Nov 2025 to Oct 13, 2025v3 Show 1 more changeShow less
    • Start date changed from estimate of Nov 2025 to Oct 13, 2025
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.
Trial Details
NCT Number NCT07157254
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Angelman Syndrome
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov